No Data
No Data
心瑋醫療-B:年度報告 2023
Interpretation of Xinwei Medical-B (6609.HK) Annual Report: Innovation and Globalization, Therapeutic Products Save Development Potential
The concept of “new quality productivity” was emphasized many times during the two sessions. In particular, the medical device industry, the high-end medical device sector, which is driven by scientific and technological innovation as the core driving force, is undoubtedly also moving towards a rapid development path as an important indicator for measuring the country's level of high-tech development.
Xinwei Medical-B (06609.HK): Expected volume of therapeutic products in 2023 is slightly lower than expected
The 2023 results were slightly lower than our expectations for the company to announce 2023 results: revenue of $232 million, +27% year over year; net loss to mother of $94 million ($200 million in 2022). Due to 2H23
Xinwei Medical-B (06609.HK) announced annual results: business focus on driving product structure transformation, gross margin rose to 70.5%, losses narrowed, and major neurointerventional treatment devices are about to be launched
Gelonghui March 28 | Xinwei Medical-B (06609.HK) announced its annual results. For the year ended December 31, 2023, the company's revenue increased to RMB 232.3 million, an increase of 26.9% year on year, and loss before tax narrowed to RMB 102.9 million, a year-on-year decrease of 48.9%. With the expansion of business scale and the effects of cost control and efficiency measures, the company's gross margin increased 2.6 percentage points to 70.5%, and the share of sales and distribution expenses and administrative expenses decreased to 66.2% (2022:91.8%). In 2023, in order to adapt to a rapidly changing city
Xinwei Medical-B (06609) announced 2023 annual results with revenue of 232 million yuan, an increase of 26.9% year-on-year
Xinwei Medical-B (06609) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 232 million yuan (RMB, same below) during the period, an increase of 26.9%; the parent company's owners should have accounted for a loss of 94.012 million yuan, a year-on-year decrease of 53.08%; and a basic loss of 2.47 yuan per share.
HEARTCARE-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
No Data